Company intelligence / Profile preview

D.A.S.T. BIOTECH PHARM

Suzhou, China

Ownership: Private
Development stage: Other

Overview

DAST Biotech is an early-stage biotechnology company focused on the development of innovative therapies for metabolic diseases, including type 2 diabetes and obesity. The company specializes in the design of multi-agonist peptides and small molecules targeting key metabolic receptors such as GLP-1, GIP, and Glucagon. DAST Biotech aims to leverage its expertise in peptide engineering to create next-generation treatments with improved efficacy and safety profiles. The company's research and development efforts are primarily centered on addressing the growing global burden of metabolic and endocrine disorders.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on D.A.S.T. BIOTECH PHARM.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D.A.S.T. BIOTECH PHARM.

Explore the full profile